IVERIC bio, Inc. which can be found using ticker (ISEE) now have 12 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The range between the high target price and low target price is between 40 and 31 with the average target price sitting at $39.25. Given that the stocks previous close was at $37.09 this now indicates there is a potential upside of 5.8%. The 50 day moving average now sits at $30.46 while the 200 day moving average is $22.25. The company has a market capitalization of 5.24B. The stock price for Iron Mountain Incorporated is 38 USD
The potential market cap would be $5,540,667,672 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of – and a -29.64% return on assets.
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
